9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

A. Inoue, T. Nukiwa, Makoto Maemondo et al.|European Journal of Cancer Supplements|2009

Cited by 15